Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 13 recruiting now early-phase tilt

Basal Cell Carcinoma: early-phase trial registry

13 of 25 indexed Basal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #652 of 28,707 conditions by registered trial count.

25 US clinical trials · 13 currently recruiting · #652 of 28,707 conditions by registered trial count

Basal Cell Carcinoma: 25 US clinical trials tracked, 13 recruiting.

Basal Cell Carcinoma is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition basal-cell-carcinoma

OPEN 13 | RECR 52% | LATE 1 | EARLY 13 | RANK #652 | SPON 4

Nearest open-share peer: Amblyopia (52% recruiting · 25 trials)

Basal Cell Carcinoma (this)52%Alpha-1 Antitrypsin Deficien48%Alcohol Use40%Acute Lymphocytic Leukemia36%Alcohol-Related Disorders36%
Open-enrollment share among volume-matched conditions near Basal Cell Carcinoma

Basal Cell Carcinoma lists 13 open slots (52% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Basal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Basal Cell Carcinoma is recruiting above its size-band peers.

    13 of 25 indexed trials (52%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Basal Cell Carcinoma research.

    Memorial Sloan Kettering Cancer Center accounts for 4 of 25 trials (16%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Most Basal Cell Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 25 trials that report a genuine target (sentinel values excluded). 21 of those (84%) plan for fewer than 100 participants.

  4. Basal Cell Carcinoma research is mostly interventional.

    19 interventional and 6 observational studies make up this index (76% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 28Phase 41

Open and recent trials

25 total, page 1 of 1

RECRUITING Phase 1 115 participants

A Beta-only IL-2 ImmunoTherapY Study

Medicenna Therapeutics

NCT05086692

RECRUITING Phase 1 90 participants

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

Replimune

NCT04349436

RECRUITING Phase 2 80 participants

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Stamford Pharmaceuticals

NCT06344052

RECRUITING NA 60 participants

Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas

Roswell Park Cancer Institute

NCT07182240

RECRUITING Phase 2 57 participants

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03521830

RECRUITING Phase 1 56 participants

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

NCT05859074

RECRUITING NA 52 participants

Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy

University of Rochester

NCT06473103

RECRUITING NA 40 participants

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

Christopher Zachary

NCT04744935

RECRUITING Phase 2 30 participants

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

University of California, San Diego

NCT06624475

RECRUITING Phase 2 28 participants

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Case Comprehensive Cancer Center

NCT05020912

RECRUITING Phase 2 27 participants

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Mayo Clinic

NCT07285044

RECRUITING 20 participants

Raman Spectroscopy and Skin Cancer

Renee Farrell

NCT06384924

RECRUITING Early Phase 1 10 participants

CivaDerm(TM) Surface Therapy Pilot Study

CivaTech Oncology

NCT04480645

ACTIVE NOT RECRUITING Phase 2 38 participants

A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma

Memorial Sloan Kettering Cancer Center

NCT05294120

ACTIVE NOT RECRUITING 26 participants

A Study of Observation and Follow-up in People With Basal Cell Carcinoma

Memorial Sloan Kettering Cancer Center

NCT05473507

ACTIVE NOT RECRUITING Phase 1 25 participants

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

SkinJect

NCT04928222

COMPLETED 1,111 participants

DERM US and EU Validation Study

Skin Analytics Limited

NCT05126173

COMPLETED 187 participants

Electronic Brachytherapy for the Treatment of NMSC

Xoft

NCT01016899

COMPLETED 180 participants

Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H and E Histology

Abramson Cancer Center at Penn Medicine

NCT01540695

COMPLETED NA 75 participants

Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

Mayo Clinic

NCT00578214

COMPLETED Phase 4 49 participants

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

The University of Texas Health Science Center, Houston

NCT00581425

COMPLETED 45 participants

Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins

Memorial Sloan Kettering Cancer Center

NCT01872130

COMPLETED Phase 2 40 participants

Photochemical Tissue Bonding

Massachusetts General Hospital

NCT00586040

COMPLETED Phase 2 32 participants

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

Sirnaomics

NCT04669808

COMPLETED NA 32 participants

Video-Based Treatment Options for Basal Cell Carcinoma

Emory University

NCT02158650

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 8
Phase 4 1

Top Sponsors

Named interventions

Most-linked intervention names on Basal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Nivolumab Drug
2 trials
Deep Ensemble for the Recognition of Malignancy (DERM) Device
1 trials
electronic brachytherapy Radiation
1 trials
Video-Based Informed Consent Behavioral
1 trials
STP705 Drug
1 trials
sutures Procedure
1 trials
tissue bonding Procedure
1 trials
Prospective Midazolam Drug
1 trials

US sites by state

Facility locations filed on Basal Cell Carcinoma trials. A trial with sites in several states counts in each.

New York 11 trials
Florida 7 trials
California 6 trials
Texas 4 trials
New Jersey 3 trials
Massachusetts 3 trials
Arizona 3 trials
Pennsylvania 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Basal Cell Carcinoma page

25 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Basal Cell Carcinoma condition card totals 25 registered trials; most-linked intervention Nivolumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.